AoU Research Priorities Use Cases

What are the genetic, comorbid risk factors, and anticancer agents that contribute to heart failure after cancer therapy

Goals:To study the epidemiology of cardiovascular complications of cancer therapy in order to design prevention strategy and precision treatment of cancer patients while minimizing debilitating cardiovascular complications. Methods: compare data on genetic, co morbid risk factors, and anticancer agents used in association with cardiovascular complications after cancer therapy. Expected outcomes: This study will provide much needed data on cardiovascular toxicity of anticancer agents.

The remaining questions allow you to outline in more detail the information needed to address your research question. The series of questions allow up to five entries. If you have more than five entries, please try to prioritize them and enter the remainder in the final field. When done, click Submit at the bottom. No

Select your required Data Item #1, which is most important to your study. This would be an item that needs to be generated and collected from different sources using various procedures, tools, techniques, assays, etc. If not in the current selection, please enter it in the textbox below. Cancer incidence

If you did not find your Data Item #1 in the dropdown selection above, please enter it here. Cancer diagnosis

By what method will Data Item #1 be obtained? This may Include procedures, tools, techniques, assays, and analytical approaches for the collection, measurement, or analysis of data. If you do not find the required method, you may enter it in the textbox below. Linkage with virtual tumor registry to ensure complete case ascertainment

Are there specifications that apply to the method by which Data Item #1 will be obtained, e.g., is the measurement taken once a year, every month, or some other variation? If you do not find your specification in the dropdown, you may enter it in the textbox below. At specified times anchored to the clinical event

Data Item #2 Current medication use

Method #2 Prescription records

Specification #2 Continuous monitoring

If Specification #2 was not in the dropdown, please enter it here: Continuous monitoring after confirmation of cancer diagnosis

Data Item #3 History, cardiac

If Data Item #3 was not in the dropdown, please enter it here cardiovascular history prior to diagnosis of cancer

Method #3 Electronic Health Records (EHR)

If Method #3 was not in the dropdown, please enter it here clinical diagnostic tests upon the diagnosis of cancer,eg. baseline echocardiogram.

Specification #3 At specified times anchored to the clinical event

Data Item #4 Heart testing results

If Data Item #4 was not in the dropdown, please enter it here cardiovascular clinical events and test results after cancer diagnosis

Method #4 Electronic Health Records (EHR)

If Method #4 was not in the dropdown, please enter it here clinical dignostic tests results

Specification #4 At specified times anchored to the clinical event

If Specification #4 was not in the dropdown, please enter it here plus yearly cardiac screaning for unreported events

Data Item #5 Brain Natriuretic Protein (BNP)

If Data Item #5 was not in the dropdown, please enter it here and high sensitivity cardiac troponin I

Method #5 Blood test

Specification #5 At specified times anchored to the clinical event

If Specification #5 was not in the dropdown, please enter it here and every 3 weeks during chemotherapy and every 3 months for a year following conclusion of therapy.

If you have more than five data items, you may enter them here.

Genome and SNPs (single nucleotide polymorphisms) sequencing upon the diagnosis of cancer
To study genetic difference in sensitivity to anticancer therapy and associated cardiovascular toxicity. For example, Patients with higher expression of Topoisomerase 2 beta may be more susceptible to doxorubicin induced cardiac toxicity.

Voting

11 votes
Ideate
Idea No. 333